Reduced Hypoglycemia and Increased Time in Target Using Closed-loop Insulin Delivery During Nights with or Without Antecedent Afternoon Exercise in Type 1 Diabetes
Overview
Authors
Affiliations
Objective: Afternoon exercise increases the risk of nocturnal hypoglycemia (NH) in subjects with type 1 diabetes. We hypothesized that automated feedback-controlled closed-loop (CL) insulin delivery would be superior to open-loop (OL) control in preventing NH and maintaining a higher proportion of blood glucose levels within the target blood glucose range on nights with and without antecedent afternoon exercise.
Research Design And Methods: Subjects completed two 48-h inpatient study periods in random order: usual OL control and CL control using a proportional-integrative-derivative plus insulin feedback algorithm. Each admission included a sedentary day and an exercise day, with a standardized protocol of 60 min of brisk treadmill walking to 65-70% maximum heart rate at 3:00 p.m.
Results: Among 12 subjects (age 12-26 years, A1C 7.4±0.6%), antecedent exercise increased the frequency of NH (reference blood glucose<60 mg/dL) during OL control from six to eight events. In contrast, there was only one NH event each on nights with and without antecedent exercise during CL control (P=0.04 vs. OL nights). Overnight, the percentage of glucose values in target range was increased with CL control (P<0.0001). Insulin delivery was lower between 10:00 p.m. and 2:00 a.m. on nights after exercise on CL versus OL, P=0.008.
Conclusions: CL insulin delivery provides an effective means to reduce the risk of NH while increasing the percentage of time spent in target range, regardless of activity level in the mid-afternoon. These data suggest that CL control could be of benefit to patients with type 1 diabetes even if it is limited to the overnight period.
7. Diabetes Technology: Standards of Care in Diabetes-2025.
Diabetes Care. 2024; 48(Supplement_1):S146-S166.
PMID: 39651978 PMC: 11635043. DOI: 10.2337/dc25-S007.
Nutritional Management of Athletes with Type 1 Diabetes: A Narrative Review.
Cavallo M, De Fano M, Barana L, Dozzani I, Bianchini E, Pellegrino M Nutrients. 2024; 16(6).
PMID: 38542818 PMC: 10975101. DOI: 10.3390/nu16060907.
Turner L, Marak M, Gal R, Calhoun P, Li Z, Jacobs P Diabetologia. 2024; 67(6):1009-1022.
PMID: 38502241 DOI: 10.1007/s00125-024-06127-2.
Recent advances in the precision control strategy of artificial pancreas.
Ming W, Guo X, Zhang G, Liu Y, Wang Y, Zhang H Med Biol Eng Comput. 2024; 62(6):1615-1638.
PMID: 38418768 DOI: 10.1007/s11517-024-03042-x.
7. Diabetes Technology: Standards of Care in Diabetes-2024.
Diabetes Care. 2023; 47(Suppl 1):S126-S144.
PMID: 38078575 PMC: 10725813. DOI: 10.2337/dc24-S007.